HOME >> BIOLOGY >> NEWS
Multiple sclerosis progression linked to immune-cell substance

COLUMBUS, Ohio A new study suggests that a substance made by immune cells plays a key role in the progression of a disease in animals that closely mimics multiple sclerosis (MS). The findings further suggest that blocking the molecule, known as macrophage migration inhibitory factor (MIF) might prevent the progression of the disease.

Researchers at The Ohio State University Medical Center conducted the study using mice that develop a disease that mimics MS. They compared these animals to similar mice that lacked MIF, an immune-system signaling molecule.

The results show that the animals without MIF develop the initial, acute phase of the disease, but then show no signs of further progression.

The study is published as a Cutting Edge paper in the November 1, 2005, issue of the Journal of Immunology.

"Our results suggest that MIF may be less important for initiating MS, but that it may be necessary for MS progression," says principal investigator Caroline C. Whitacre, professor of molecular virology, immunology and medical genetics.

"These findings indicate that in the future we can perhaps use MIF levels to predict the onset of a relapse. But more importantly, perhaps this study will lead to drugs that can halt the course of MS by blocking the action of MIF."

MS is an inflammatory, autoimmune disease which primarily affects the brain and spinal cord. Autoimmune diseases occur when the body's own immune cells destroy tissues in the body. In MS, immune cells destroy the myelin sheath that surrounds nerve fibers in the brain and spinal cord. Myelin is a fatty substance that insulates nerve fibers and enables them to transmit impulses.

According to the National MS Society, about 400,000 Americans are living with MS and about 10,400 new cases are diagnosed yearly. The disease usually strikes between the ages of 20 and 40, and it is more common in women. MS symptoms vary from person to person. Some individuals
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
19-Oct-2005


Page: 1 2

Related biology news :

1. May: Multiple Sclerosis Awareness Month -- latest research is good news
2. Alleviating the burden of Multiple Sclerosis
3. Multiple genes permit closely related fish species to mix and match their color vision
4. Multiple genetic flavors may explain autism
5. Multiple sightings of long-lost woodpecker reported
6. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
7. Research teams uncover risk genes for multiple sclerosis
8. First new multiple sclerosis gene found in 30 years
9. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
10. Risk genes for multiple sclerosis uncovered
11. High cholesterol diets modify gene expression in atherosclerosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2019)... ... January 10, 2019 , ... When Dr. James L. Sherley, ... was invited to contribute a chapter to the new book Perinatal Stem Cells: Research ... Asymmetrex’s effort to address a debilitating secret of stem cell medicine. For more ...
(Date:1/7/2019)... ... 07, 2019 , ... Concerto HealthAI, a technology leader in ... oncology and other key therapeutic areas, and its Chief Executive Officer, Dr. Jeff ... spanning the entire healthcare landscape, on January 8, 2019, at 2:30 p.m. in ...
(Date:1/4/2019)... , ... January 03, 2019 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field! Visit http://www.xtalks.com to check out our upcoming webinars, or ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... ... January 08, 2019 , ... The American Society of Gene and ... by a selection committee made up of industry leaders identified by the ASGCT board ... are mentored awards created to support ASGCT members designing transformative pilot studies in gene ...
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life , a ... blood, has been named as a partner in Medigen Biotech’s upcoming cell therapy ... for cancer treatment, will use CellMax Life’s circulating tumor cell platform CMxTM, in ...
(Date:12/19/2018)... Md. (PRWEB) , ... December 19, 2018 , ... ... for Life Science, announces the validated release of Limfinity® version 7.1. The new ... important technical offering from RURO as 2018 comes to an end. , Validation ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... have been given the green light to immediately begin a clinical patient trial ... The medical devices bureau of Health Canada has granted what is called an ...
Breaking Biology Technology:
Cached News: